[Aminostigmine as a cholinesterase inhibitor and as an agent for treating poisonings by cholinergic blockers].
Experiments on non-inbred albino mice have demonstrated that aminostigmine is an active reversible centrally active cholinesterase inhibitor close to the properties of physostigmine, but greatly superior to it in its action duration. Clinical examinations of healthy volunteers and patients have shown that aminostigmine-induced inhibition of cholinesterase activity persists 6 hours. The agent have been found to be more highly effective in treating cholin blocker-induced intoxications than galanthamine, which manifests itself in its greater stability of the therapeutical effect achieved and in its higher ability to prevent cardiovascular events occurring in intoxication.
Prozorovskiĭ
V B
VB
Livanov
G A
GA
Velikova
V D
VD
Afanas'ev
V V
VV
Pavlova
L V
LV
D000208:Acute Disease; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000201:enzymology; D002219:Carbamates; D018680:Cholinergic Antagonists / Q000506:poisoning*; D002800:Cholinesterase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D002802:Cholinesterases / Q000187:drug effects; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D051379:Mice; D011041:Poisoning / Q000188:drug therapy; D011725:Pyridines; D011729:Pyridostigmine Bromide / Q000031:analogs & derivatives; D013997:Time Factors
D002219:Carbamates; D018680:Cholinergic Antagonists; D002800:Cholinesterase Inhibitors; D011725:Pyridines; C070102:aminostigmine; D002802:Cholinesterases; D011729:Pyridostigmine Bromide